323
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

CD19 negative and dim precursor B-lineage acute lymphoblastic leukemias: real-world challenges in a targeted-immunotherapy era

, , , , &
Pages 3154-3160 | Received 05 Dec 2018, Accepted 19 May 2019, Published online: 11 Jun 2019
 

Abstract

Flow cytometric diagnosis and minimal residual disease (MRD) assessment of precursor B-lineage acute lymphoblastic leukemia (B-ALL) are heavily dependent on CD19 based gating strategies. However, this approach is not optimal in the diagnosis and follow-up of CD19 negative or dim B-ALLs. Though CD19 negative B-ALLs are rare, in the current era of CD19 targeted immuno-therapy, CD19 negative B-ALL relapses are frequent. We have presented our cohort of 14 de novo CD19 negative and dim B-ALLs and have highlighted the difficulties faced during diagnosis and MRD assessment of these patients. We have also discussed the need to identify alternative B-lineage gating markers and strategies to deal with such scenarios.

Acknowledgements

We would like to acknowledge Mrs. Arcot Radhakrishnan Abitha, senior scientific assistant, for her efforts in flow cytometry sample processing and acquisition. We would also like to thank Dr. Papagudi G. Subramanian and Dr. Prashant R. Tembhare from the hematopathology laboratory, Tata Memorial Center, Mumbai for their help in fine-tuning our flow cytometry assays for this manuscript.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2019.1625043.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.